ERS Genomics and Medicines Discovery Catapult sign CRISPR/Cas9 license agreement Partnership provides Medicines Discovery Catapult access to CRISPR gene editing technology across a broad range of drug discovery applications   Dublin, Ireland, and Cheshire, UK, 04 September 2024: ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, and Medicines Discovery Catapult.

  The United Nations predicts that there will be an additional 2.2 billion people on the planet by 2050. To help feed the growing population, the food industry must overcome several critical challenges, from the amount of arable land available for growing crops and the environmental demands of agriculture to.

CRISPR/Cas9 Prime Editing is a novel gene editing technique that utilizes a modified Cas9 protein to introduce mutations in the genome with a higher degree of safety and complexity. This technique represents an evolution in the CRISPR/Cas9 system that enables researchers to more safely create complex genetic changes than using.